Abstract
Depression is an affective disorder characterized by hallucination, delusion and increased social risk and is estimated to affect approximately 20 % of the population at some point during the lifetime. As per World Health Organization (WHO) it is predicted to be the leading cause of burden of disease by 2030. Effects of currently available antidepressants have explained the monoamine hypothesis of depression, which proposes that impaired release of serotonin, noradrenaline and dopamine, are thought to be responsible for the development of depressive symptoms. However, these drugs are not specific for their action, as they also inhibit other enzymes; this explains the side effects/drug interactions associated with these agents. The present review will familiarize the readers with novel targets being identified for depression which will be certainly beneficial for researcher, academician for the development of drugs for the management of depression and related behavior.
Keywords: Cholinergic receptors, cocaine and amphetamine regulated transcript peptide, depression, histaminergic receptors, N-methyl-D-aspartate, oxidative stress, substance P.
CNS & Neurological Disorders - Drug Targets
Title:Potential Targets for the Development of Novel Antidepressants: Future Perspectives
Volume: 14 Issue: 2
Author(s): Vishnu N. Thakare and Bhoomika M. Patel
Affiliation:
Keywords: Cholinergic receptors, cocaine and amphetamine regulated transcript peptide, depression, histaminergic receptors, N-methyl-D-aspartate, oxidative stress, substance P.
Abstract: Depression is an affective disorder characterized by hallucination, delusion and increased social risk and is estimated to affect approximately 20 % of the population at some point during the lifetime. As per World Health Organization (WHO) it is predicted to be the leading cause of burden of disease by 2030. Effects of currently available antidepressants have explained the monoamine hypothesis of depression, which proposes that impaired release of serotonin, noradrenaline and dopamine, are thought to be responsible for the development of depressive symptoms. However, these drugs are not specific for their action, as they also inhibit other enzymes; this explains the side effects/drug interactions associated with these agents. The present review will familiarize the readers with novel targets being identified for depression which will be certainly beneficial for researcher, academician for the development of drugs for the management of depression and related behavior.
Export Options
About this article
Cite this article as:
Thakare N. Vishnu and Patel M. Bhoomika, Potential Targets for the Development of Novel Antidepressants: Future Perspectives, CNS & Neurological Disorders - Drug Targets 2015; 14 (2) . https://dx.doi.org/10.2174/1871527313666140806121648
DOI https://dx.doi.org/10.2174/1871527313666140806121648 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets Neurochemistry Changes Associated with Mutations in Familial Parkinsons Disease
Current Medicinal Chemistry Development of a Novel and Robust Pharmacological Model of Okadaic Acid-induced Alzheimer’s Disease in Zebrafish
CNS & Neurological Disorders - Drug Targets Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer
Epigenetic Diagnosis & Therapy (Discontinued) The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology Loss in Toxic Function of Aggregates of α -Synuclein Mutants by a β-Synuclein Derived Peptide
Protein & Peptide Letters Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology Nonnucleoside Inhibitors of Adenosine Kinase
Current Pharmaceutical Design Estrogen Receptor-α: Plasma Membrane Localization and Functions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Classical Neurotransmitters and Neuropeptides Involved in Parkinson's Disease: Focus on Anti-Parkinsonian Drugs
Current Drug Therapy CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer
Current Medicinal Chemistry Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets Identification of Novel Structurally Diverse Anaplastic Lymphoma Kinase Inhibitors Based on Pharmacophore Modeling, Virtual Screening and Molecular Docking
Combinatorial Chemistry & High Throughput Screening Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design Advances in Research of Schiff-Base Metal Complexes as Potent Antioxidants
Current Medicinal Chemistry